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ABSTRACT

KAIA HORNE: EFFICACY OF 𝛥-9-TETRAHYDROCANNABINOL FOR HIV-RELATED
NEUROPATHIC PAIN
(Under the direction of Dr. Jason Paris)

Despite the availability and success of antiretroviral therapeutics, ~30% of patients living
with HIV experience neuropathic pain that is often intractable. The mechanisms are not known,
but there is evidence to support a role for the HIV virotoxins, Tat and/or gp120, which can
damage or degenerate neurons and peripheral nerves. One mechanism by which Tat and gp120
promote nerve damage involves the stimulation of proinflammatory cytokine production from
immune cells which can damage or kill bystander cells. Notably, compounds found in Cannabis
exert anti-inflammatory effects and many studies report HIV patients to consume more
marijuana than seronegative individuals. When people living with HIV were asked about their
pain management, many suggested that marijuana improved their symptoms. As such, we
hypothesized that a component of cannabis, 𝛥-9-tetrahydrocannabinol (THC), exerts antiinflammatory effects that can offset the proinflammatory profile of HIV gp120. THC was
screened in human microglia for its capacity to reduce gp120-mediated inflammation. While
THC may exert acute anti-inflammatory effects, long-term marijuana use is associated with
cognitive perturbation and reduced immune function. THC contributes to the psychotropic
activity of cannabis. Thus, the benefits must be weighed against the adverse effects. Future work
will assess cannabis constituents that may exert anti-inflammation without psychotropic activity.
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1. Introduction
Human Immunodeficiency Virus (HIV) is a sexually-transmitted disease that affects
one’s immune system for the rest of their life. As of 2020, approximately 37.7 million people
around the world are living with HIV (UNAIDS, 2021). In the U.S., it was estimated that there
were about 1,189,700 people infected with HIV in 2019 (CDC, 2021). This number included an
approximation of U.S. citizens who were undiagnosed by a physician. Sexual transmission
appears to account for about 70% of HIV transmission while drug use via injection and vertical
transmission account for the remainder of cases (Shaw & Hunter, 2012). The risk of infection
occurs through sharing bodily fluids with another person, sharing needles, or from maternalinfant transmission during any part of pregnancy or delivery. Socioeconomic factors of a society
also play an important role in transmission. The most affected populations include Black/African
American and Hispanic/Latino groups and those who identify as homosexual or bisexual men
(CDC, 2021). The overall goal to end the HIV epidemic is to decrease the number of new HIV
diagnoses (CDC, 2021).

Mechanisms of HIV
HIV is a retrovirus disease that is made of a single stranded RNA genome. There are two
types of HIV: HIV-1 and HIV-2. They are structurally similar, but this thesis will focus on HIV1. HIV-1 can progress to acquired immunodeficiency syndrome (AIDS) if untreated. The HIV
virion contains the gag gene which encodes for the structural proteins in its core, the env gene
which encodes the viral envelope glycoproteins: gp120 and gp41, and the pol gene which
encodes for the enzymes, reverse transcriptase, integrase, and protease, which are crucial for
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viral replication (Fanales-Belasio, et al. 2010). Once HIV enters the body, T helper cells
recognize the foreign virion and relocate to the site of initial infection and signal other cells to
help rid the body of infection. The gp120 proteins on the HIV envelope attach to the CD4+
molecules on the T-helper cells, macrophages, and monocytes to fuse the HIV particle to the host
cell with the help of gp41 (Al-Jabri, et al. 2003). Once fused together, the HIV particle will shed
its protein coat, activating the enzyme reverse transcriptase to transcribe the RNA to
complementary DNA. Ribonuclease H then works to create a double strand DNA molecule by
making a complementary DNA strand to the previous strand. The enzyme integrase will then
incorporate the newly formed viral DNA into the host cell DNA. The viral DNA then undergoes
transcription to form mRNA and regulatory proteins, Tat and Rev. Tat encourages transcription
and formation of longer RNA strands while Rev facilitates the process and promotes the
formation of mature viral particles. The viral mRNA that is created enters the cytoplasm to form
new virions with the help of pol, gag, and env genes to create the structures of a new HIV
particle (Fanales-Belasio, et al. 2010). The protease is important in cleaving the gag and pol
proteins for viral assembly along with initiating apoptosis of the cell (Fanales-Belasio, et al.
2010; Mbita, et al. 2014). As HIV spreads throughout the body, it causes the loss of CD4+ T
lymphocytes through apoptosis (Stefanou, et al. 2019).

NeuroHIV and Pain
Approximately 15-55% of people living with HIV meet the criteria for neuroHIV (a
constellation of neurological disorders that include cognitive impairment, mood disorders, and
motor deficits) (Saylor, et al. 2016). Many individuals who are diagnosed with HIV experience
intractable pain throughout their lives. Intractable pain is a chronic form of pain that is not
2

curable, so the focus of treatment is to manage pain (Roland & Sampson, et al. 2017). The HIV-1
proteins, Tat and gp120, promote neuropathic pain in via several mechanisms including the
activation of immune cells and the stimulation of pro-inflammatory cytokines and chemokines.
Tat is a neurotoxin that increases calcium levels, neuronal death, and dendritic degeneration
(Hermes, et al. 2018). gp120 is an envelope protein of HIV can promote apoptosis of cells and
prevents neurogenesis (Avraham, et al. 2014). As gp120 leaves the cell, it will interact with
glutamate to activate the N-methyl D-aspartate (NMDA) receptors, which leads to neurotoxicity
(Dawson, et al. 1993). gp120 activates C-X-C Chemokine Receptors Type 4 (CXCR4) on
microglia, neurons, and astrocytes to release inflammatory cytokine IL-𝛽 which leads to the
activation of a ubiquitin ligase and NMDA receptors through increased glutamate sensitivity
(Kim, et al. 2011). This process can lead to inflammation and synapse loss. These proteins
promote neuroinflammation by acting alone or in concert with each other and other HIV-related
virotoxins. The net effect of these actions can result in chronic pain due in part to nerve and
neuron damage. In looking for a solution, many patients reported the use of cannabis to alleviate
pain. In a study conducted to determine the effectiveness of cannabis, it was seen that many
participants experience pain relief in addition to an improvement in mood and daily functioning
(Ellis, et al. 2009).

Potential Mechanisms of HIV-mediated Pain
Inflammation occurs when the immune system responds to tissue injury with the use of
cell recruitment and mediator release (Ellis, et al. 2013). Neuroinflammation is largely mediated
by activation of astrocytes and microglia (the macrophage of the brain). Pro-inflammatory
cytokines contribute to pain experienced by HIV+ individuals. Glia cells might also be a cause
3

for HIV-mediated pain through the release of glutamate (Cairns, et al. 2015). Peripheral
sensitization can occur after nerve lesion in the absence or presence of tissue inflammation (von
Hehn, et al. 2012). Central sensitization occurs when the brain experiences a strong pain signal in
the absence of inflammation in the periphery (Merlin, et al. 2014). A lower CD4+ T cell count is
associated with pain in individuals (Aouizerat, et al. 2010).

Current HIV Therapeutic Treatments
Pre-exposure prophylaxis (PrEP) can prevent HIV infection and combination
antiretroviral therapy (cART) is used to decrease the viral replication after HIV infection has
occurred. cART attenuates some associated comorbidities. This is accomplished by combining
multiple antiretroviral agents that will interact well together to attack multiple symptoms
(Maenza & Flexner, et al. 1998). When patients were treated with antiretroviral agents for
greater than 12 months, they were less likely to show multinucleated giant cells or diffuse myelin
pallor (Glass, et al. 1993). PrEP is a preventative drug that is prescribed to individuals who have
been exposed to HIV or have a greater chance of contracting it, but have not yet been diagnosed
with the disease (NIH, 2021). While these therapies have proven effective, they do not cure the
disease. They also lack the ability to target some HIV neurotoxic proteins. cART has allowed
people diagnosed with HIV to live longer lives, but it does not alleviate pain associated with HIV
rather it has turned it into a chronic condition (Yuan & Kaul, et al. 2019).
Palliative care is an approach to improve the overall quality of life of a patient by
treating physical, psychosocial, and spiritual problems (Rasche, et al. 2019). HIV is associated
with many other infections and illnesses as it will lower an infected person’s immune system as

4

their white blood cells are affected. Cannabis and cannabinoids are being considered as a
therapeutic to resolve chronic pain and other intense symptoms (Rasche, et al. 2019).

HIV is Associated with Cannabis Use/Abuse
Approximately 77% of HIV infected adults report lifetime marijuana use (Montgomery,
et al. 2019). There are many contradictions as to whether cannabis use is helpful or harmful to
individuals with the disease. Cannabis overuse or abuse can often occur with the ingestion of
edibles as many individuals underestimate the effects of cannabis in their body (Kelly, et al.
2021). New synthetic drugs have a stronger binding affinity to CB1 than Δ-9tetrahydrocannabinol (THC) and can lead to symptoms such as hallucination and paranoia
(Heinbockel, et al. 2018). Some articles suggest that use of cannabis can increase the chances of
HIV progressing to AIDS diagnosis (Tindall, et al. 1988).

Potential Therapeutic Effects of Cannabinoids
There are many mechanisms of Tat and gp120 that can be associated with causing pain in
HIV+ individuals. One way in which Tat causes pain is by affecting the length, volume, and
process filaments of dendritic cells. A study found that pretreating cells with Fatty acid amide
hydrolase (FAAH) enzyme inhibitor PF3845 can counteract the effects of Tat by maintaining
normal Ca2+ levels and dendritic volume and preventing neuronal cell death (Hermes, et al.
2018). Endocannabinoids, N-arachidonoyl ethanolamine (anandamide/AEA) and 2arachidonoylglycerol (2-AG), use the CB1 receptor to protect cells against Tat (Xu, et al. 2017).
One way to inhibit the activity of gp120 may be to target the chemokine receptor binding sites on
the host cell (Caffrey, et al. 2011). Mannose binding lectin and silver nanoparticles are capable
of attaching to the binding sites to block the entry of gp120 from multiple strains of HIV
5

(Caffrey, et al. 2011; Ezekowitz, et al. 2003). 12-residue peptide 1 is also shown to block gp120
at CD4+ and co-receptor binding sites (Umashankara, et al. 2010).
It is hypothesized that THC may ameliorate gp120-induce inflammation. If true, this may
be one mechanism by which cannabis can alleviate HIV-related pain. While this thesis was
interrupted by the SARS-CoV-2 pandemic, some pilot data were collected to assess the influence
of THC and/or gp120 on a human microglial cell line grown in culture. Given that there is higher
affinity to CB1 and CB2 at nanomolar concentrations (Stella, et al. 2010), a medial concentration
of 100 nM was used as well as a higher concentration of 1000 nM. It was expected that gp120
would promote microglial morphology consistent with proinflammation and THC would
attenuate this.
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2. Materials and Methods
2.1 Chemicals
THC was obtained from the Marijuana Research Laboratory at the University of
Mississippi (University, MS, USA) and was diluted to stock concentration in DMSO (10 µM).
Recombinant gp120ADA was purchased from ImmunoDx (Woburn, MA, USA; #1081) and was
diluted to a concentration in ddH2O.
2.2 Cell Culture
Human brain microglia cells (HMC3) were obtained from the American Type Culture
Collection (ATCC, Manassas, VA, USA; #CRL-3304). HMC3 cells were seeded onto 24-well
plates at a density of 5 × 103 /well. Cells were maintained at a temperature of 37℃ (5% CO2) in
growth medium: 89.5% EMEM (Life Technologies, Carlsbad, CA), 10% heat-inactivated fetal
bovine serum (FBS; Thermo Scientific Hyclone, Logan, UT), and 0.5% antibiotic/antimycotic
mixture (Life Technologies). Cells were not used beyond passage 8.

2.3 Procedure
Twenty-four hours after seeding, cells were treated with THC (diluted in media to a final
concentration of 100 nM or 1,000 nM) and/or gp120 (diluted in media to a final concentration of
500 pM) and incubated (37℃, 5% 𝐶𝑂2 ) for 24 h. Cells were fixed with paraformaldehyde (4%)
and processed for immunocytochemistry as described below.

2.4 Immunocytochemistry
Fixed cells were permeabilized (Triton X - 100 0.1%) and blocked (BSA 0.1%) for 30
mins and incubated overnight (4℃) with primary antibodies to ionized calcium-binding adaptor
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protein (Iba-1, rabbit, 1:250). Following this, cells were incubated with an anti-rabbit secondary
antibody (AlexaFluor 594, 1:500). Morphology was used to measure microglial activation
(Davis, et al. 1994; Yoichi, et al. 1999). Microglia was scored on a scale of 1-3, based on the
established scoring system for microglia morphology and phenotypes (Davis, et al. 1994; Yoichi,
et al. 1999; Ladeby, et al. 2005): 1 = resting state with long processes extending from a circular
cell body, 2 = active/reactive state with shorter and thicker processes and increased
immunoreactivity in the cell body, 3 = reactive microglia that are phagocytic and show a cell
body that is absent of extended processes.

2.5 Statistical Analyses
Data were analyzed via repeated measure ANOVA with gp120 exposure as the betweensubjects factor and THC concentration as the within-subjects concentration. If present, main
effects were to be delineated by Fisher’s PLSD post hoc test and interactions were to be
delineated by simple main effects and main effect contrasts with alpha corrected for familywise
error. Alpha was set at 0.05 for all analyses.
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3. Results
3.1 - Finding 1: There was no significant effect of THC on gp120 infected cells.
HMC3 cells were classified based on their morphology. Each morphological state
was independently graphed to determine the percent of each phenotype in the
environment after treatment. No significant effects of gp120 nor THC were observed on
the proportion of cells that were resting (Fig. 1), activated (Fig. 2), ameboid (Fig. 3), or
on the activation scale of HMC3 cells (Fig. 4).

Figure 1: Percent resting phenotype after exposure to gp120 and/or THC
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Figure 2: Percent active/reactive phenotype after exposure to gp120 and/or THC
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Figure 3: Percent phagocytic phenotype after exposure to gp120 and/or THC
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Figure 4: Activation scale of HMC3 cells after exposure to gp120 and/or THC
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4. Discussion
It was hypothesized that administering THC on to cells that had been exposed to gp120
would ameliorate its effects. gp120 is critical for HIV infection of a cell. It was believed that
targeting gp120 can attenuate HIV replication as is the therapeutic strategy behind some novel
antiretrovirals such as Maraviroc. In the experiment performed, THC did not decrease the
negative effects of gp120. This outcome could be due to ineffective binding of THC to
cannabinoid receptor, CB2, and was driven by high variance. Expanding the dose-response
concentration curve would assess whether concentrations with greater CB2 binding affinity
would yield more consistent results. As well, replication of the current experiment, beyond what
could be conducted given the SARS-CoV-2 pandemic, is expected to reduce variance. Further, a
lack of protection by THC could have also been due to actions at receptors associated wuth
psychoactive effects, rather than anti-inflammatory effects.

Cannabis and Cannabinoids
Cannabinoids can be placed into three different groups: phytocannabinoids (or natural
cannabinoids), synthetic cannabinoids, and endocannabinoids. Synthetic cannabinoids, or
artificial cannabinoids, are made in a lab for therapeutic purposes. Natural cannabinoids can be
found in plants and wildlife as they grow naturally in our ecosystem. Cannabis is made up of the
phytocannabinoids, Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Both components
have shown to be capable of positive and negative effects. THC is a psychoactive ingredient that
can cause euphoria, relaxation, anxiety/paranoia, impairments in attention and memory, and
many more effects (D’Souza, et al. 2008). CBD is a non-psychoactive ingredient that produces
an anti-inflammatory response through the reduction of cytokines (Petrosino, et al. 2018).
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Endocannabinoids are produced by an individual’s neuronal cells to defend against foreign
agents. The endocannabinoids, N-arachidonoyl ethanolamine (anandamide/AEA) and 2arachidonoylglycerol (2-AG), are ligands for G-protein coupled receptors, CB1 and CB2 (de
FONSECA, et al. 2005). CB1 receptors are mainly expressed in the central and peripheral
neurons while CB2 receptors are mainly expressed in the immune cells (Pertwee, et al. 2008).
CB1 receptors were associated with increased calcium levels in astrocytes (Navarette, et al.
2008). This suggests that CB1 receptors may play a role in cannabinoid addiction and pain. CB1
controls neurotransmitter release in order to maintain homeostasis and prevent excessive
neuronal activity in the central nervous system (CNS) (Walter, et al. 2004).

Cannabinoids that are Used Clinically
Dronabinol, Cannabidiol, and Nabilone are approved drugs by the U.S. Food and Drug
Administration (FDA) that treat nausea and appetite loss associated with HIV. The FDA has
approved the use of drug brands, marinol (active ingredient dronabinol) and cesamet (active
ingredient nabilone) (FDA, 2021). Nabilone is prescribed as 1 mg capsules (Sheikh, et al. 2021).
Dronabinol is administered in doses ranging from 2.5 mg-10 mg to be most effective (Sheikh, et
al. 2021). Low doses of dronabinol significantly increase food and caloric intake and higher
doses improve weight gain (Haney, et al. 2007). There seemed to be no effect in cognitive
function associated with this drug (Haney, et al. 2007). Dronabinol is also associated with an
improvement in mood and nausea in most patients (Beal, et al. 1995).
Cannabidiol (CBD) is a common substance that is available over the counter in many
forms including oils and is an inverse agonist drug at the CB2 receptor that has been found to
cause an anti-inflammatory response. It is an inverse agonist drug at the CB2 receptor that can
14

inhibit immune cell migration (Pertwee, et al. 2008). There has been difficulty administering
CBD orally so alternative forms are being considered. A new technique using self-emulsifying
drug delivery system improved the bioavailability of CBD to avoid build-up in the
gastrointestinal tract (Knaub, et al. 2019).

Potential Mechanisms of Cannabis to Alleviate HIV-neuropathic Pain
The cannabinoid agonist, WIN55,212-2, caused concentration dependent inhibition of
nitrite production in addition to protecting cells from Tat-induced cytotoxicity (Esposito, et al.
2022). It also protects the brain tissue against ischemic injury, but is not effective at higher
concentrations (Nagayama, et al. 1999). Activation of the CB1 receptor decreases the amount of
glutamate released which inhibits excitatory synaptic responses in the striatum (Gerdeman, et al.
2001). CB1 is also shown to provide protection against acute excitotoxic seizures associated with
glutamatergic cortical neurons (Monory, et al. 2006). THC can bind to CB1 or CB2, but has a
higher affinity of CB1 mechanisms to mediate its effects (Pertwee, et al. 2008).

Cannabis Use on Cognitive Function
Chronic or long-term use of cannabis can have negative effects on cognitive function.
Moderate to heavy use of marijuana is also associated with neurocognitive decline (Thames, et
al. 2016). There is an association of early marijuana use with memory impairment (Skalski, et al.
2018). Another study showed delayed memory associated with marijuana use rather than
complete memory loss (Cristiani, et al. 2004). THC can impair basic motor functions and
executive cognitive functions (Crean, et al. 2011). It was also found that HIV+ light marijuana
users performed better at verbal fluency tests than HIV- light marijuana users (Thames, et al.
15

2016). By targeting the endocannabinoid system, there is a possibility to suppress the neuronal
damage that occurs in HIV-associated neurocognitive disorders (HAND) (Wu, et al. 2019).

Cannabis may be helpful for other comorbidities - HIV wasting
Some of the most common comorbidities are heart failure, chronic pulmonary disease,
and renal disease (Boersma, et al 2014). HIV is also associated with a loss in appetite and decline
in mental health and associated psychological symptoms. In a study, participants with multiple
HIV-related symptoms were more likely to develop a psychiatric disorder or drug dependence
disorder (Bing, et al. 2001). There was a significant association of HIV encephalitis that was
seen by the presence of giant cells in white matter (Bell, et al. 1998). Another study showed the
effects of administering dronabinol to HIV+ individuals. It found that there was a great
improvement in appetite, mood, and nausea in patients with AIDS-related anorexia (Beal, et al.
1995).

HIV viremia
The placenta is responsible for delivering nutrients and providing protection against HIV
through cytokines and chemokines. It is believed that drugs of abuse such as cannabis may affect
the expression of cytokines and chemokines to stimulate vertical transmission (Wang, et al
2011). The synthetic cannabinoid CP55,940 inhibits activity through CB1 or CB2 in a
concentration dependent manner (Rock, et al. 2007). Synthetic cannabinoid, WIN55,212-2, binds
with low affinity to CB1 and CB2 receptors and selectively blocks G protein-gated inwardly
rectifying potassium channels 1 and 2 (GIRK1/2) neuronal excitability in the brain (An, D, et al.

16

2021). Higher viremia at cART initiation is associated with slower viral suppression (Krastinova,
et al. 2015).

Biological Mechanisms vs. Behavioral Mechanisms for adverse HIV outcomes and poor cART
response with cannabis use
There are some cases in which cART is unable to restore CD4+ T cell levels to normal
(Palmer, et al. 2016). It is suggested that starting cART during primary HIV infection can have a
negative impact on long-term immune response if interruptions occur (Krastinova, et al. 2015). It
would be better to start cART therapy in the chronic phase of HIV to avoid a greater loss of
CD4+ T cells (Krastinova, et al. 2015).

Structural Changes by HIV and or Cannabinoids
Reverse transcription-polymerase chain reaction (RT-PCR) was done on the brain tissue
of HIV patients and it found a correlation of expression for mRNA for tumor necrosis factoralpha (TNF-𝛼) with cognitive impairment and patterns of neurological changes (Glass, et al.
1993). Changes in grey matter have been detected through the use of magnetic resonance
imaging (MRI; with contrast). In a functional magnetic resonance imaging (fMRI) scan,
individuals who are using cannabis showed lower neural activity in the dorsal prefrontal cortex,
dorsal and ventral striatum, amygdala, and parahippocampal gyrus (Kober, et al. 2014). Heavy
marijuana use alone was associated with smaller volumes in the entorhinal cortex and fusiform
gyrus (Thames, et al. 2016). Participants diagnosed with HIV had a reduced thickness of the
cingulate gyrus (Thames, et al. 2016). Abnormalities in white matter could be seen with
Diffusion Tensor Imaging (DTI). For Barratt Impulsivity Scale Total and Attention, in the left
17

and right frontal regions, higher fractional anisotropy was associated with higher levels of
impulsivity for chronic marijuana users (Gruber, et al. 2011).

Sex Differences
In men, there was evidence that those who used marijuana at the time of the study or
previously in their life were at higher risk of mortality (Sidney, et al. 1997). Toll-like receptor 4
(TLR4) agonist lipopolysaccharide was found to cause allodynia only in male mice (Sorge, et al.
2011). Compared to men, women have higher levels of innate immune activation markers and
neopterin and coagulation makers (Cohn, et al. 2020). The activation of innate immune markers,
soluble CD163 and soluble CD14, suggested that monocyte or macrophage activation in the CNS
is associated with neuronal injury (McGuire, et al. 2015).

Effects of Cannabinoids on HIV progression
There are varying results of whether cannabinoids have an effect on the progression of
HIV to AIDS. In a study done by the Sydney AIDS project it was concluded that individuals who
progressed to AIDS and had smoked marijuana three months before the study often exhibited
lower percentage of CD4+ cells and a higher percentage of CD8+ cells than those who had not
used marijuana (Tindall, et al. 1988). This suggests that marijuana use is not associated with
reducing pain levels. In another study, participants reported cannabis use 2-3 times per week and
there was no significant association with HIV progression found in the group (Coates, et al.
1990). There was no significant association between age or the amount of drinking and smoking
done by an individual previous to the study (Coates, et al. 1990).
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Potential Limitations of Cannabinoids as HIV therapeutic
There can be negative effects associated with cannabinoids or cannabis use. The use of
THC may weaken the immune system and lead to less resistance to bacterial and viral infections
(Friedman, et al. 2003). THC is associated with an increased risk of herpes simplex virus-2 and
often resulted in more severe herpes genitalis, higher mortality rates, and high mean titers of
virus shed from the vagina (Cabral, et al. 2006). CBD increases chances of cellular death when
exposed during neuronal differentiation (Schönhofen, et al. 2015).

Limitations of the Experiment
For this experiment, we considered the effects of targeting gp120 with THC to ameliorate
the effects of HIV-related neuropathic pain. Our results showed no significant effect of THC
compared to controls. If we were to replicate this study, we would perform additional
experiments and a wider range of concentrations. The timing of incubation with THC and gp120
may also be important. Given that gp120 can be cytotoxic, longer durations of exposure may
have killed cells that would otherwise contribute to the dynamic range of the assay. A live/dead
assay will be included in future experiments to rule this out. Non-psychoactive, potentially antiinflammatory constituents of cannabis, such as CBD, should also be examined.
In conclusion, pain in HIV+ individuals may occur in part due to proinflammtory actions
of gp120. In the literature, cannabis and cannabinoids are suggested as a possible analgesic.
Current medications include dronabinol, CBD, and nabilone. THC was tested to determine its
effect on the mechanisms of gp120, but the concentrations assessed yielded variable results and
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need to be replicated. Further testing should be completed to determine if additional components
of cannabis can serve as potential therapeutics for HIV-associated neuropathic pain.
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